1 citations
,
October 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” A man developed skin lesions as a side effect of a gamma secretase inhibitor used for treating a tumor.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
12 citations
,
November 2006 in “Journal of thoracic oncology” A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.
January 2019 in “Spectrum Research Repository (Concordia University)” Topiramate impairs gene transmission in zebrafish, while Ginkgo biloba reduces harmful effects of high β-catenin levels.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
26 citations
,
December 1981 in “British journal of dermatology/British journal of dermatology, Supplement” Cyproterone acetate reduced hair growth in most hirsute females and made hair softer, thinner, and lighter.
3 citations
,
January 1990 in “Cancer chemotherapy and pharmacology” Topical thiols may prevent hair loss caused by certain chemotherapy drugs.
January 2025 in “Ege Tıp Bilimleri Dergisi” Radiotherapy affects mitochondrial-related genes in metastatic breast cancer cells.
January 2016 in “Journal of clinical case reports” Docetaxel treatment for breast cancer can cause permanent hair loss.
21 citations
,
May 1989 in “Advanced Drug Delivery Reviews” Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.
10 citations
,
July 2016 in “Clinical and translational science” Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
February 2014 in “Cancer Research” Recent findings advanced understanding of cancer mechanisms and potential treatments.
January 2024 in “Acta dermato-venereologica” 44 citations
,
June 2015 in “British Journal of Pharmacology” Betulinic acid can help treat hepatitis C by stopping virus replication.
24 citations
,
November 2013 in “British Journal of Dermatology” Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
5 citations
,
January 2021 in “Indian Journal of Pharmacology” Nilotinib can cause generalized keratosis pilaris.
25 citations
,
January 2011 in “Annals of Dermatology” Erlotinib can cause hair loss as a side effect.
March 2023 in “JAAD case reports”
6 citations
,
August 2004 in “Journal of Chemical Information and Computer Sciences” The research found a link between certain molecular features and the biological activity of BC3, which can help identify or create new active compounds.
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
3 citations
,
August 2019 in “JAAD Case Reports” Temporary hair loss can occur after 5-fluorouracil treatment for keloids.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
January 2004 in “Headache” Divalproex sodium significantly improved headaches in two-thirds of patients.
2 citations
,
December 2015 in “DOAJ (DOAJ: Directory of Open Access Journals)” Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.